Pacific Wealth Strategies Group Inc. Has $383,000 Stake in Pfizer Inc. (NYSE:PFE)

Pacific Wealth Strategies Group Inc. decreased its stake in shares of Pfizer Inc. (NYSE:PFE) by 70.2% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 9,771 shares of the biopharmaceutical company’s stock after selling 23,065 shares during the quarter. Pacific Wealth Strategies Group Inc.’s holdings in Pfizer were worth $383,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Cullinan Associates Inc. grew its position in Pfizer by 1.2% in the 4th quarter. Cullinan Associates Inc. now owns 250,489 shares of the biopharmaceutical company’s stock valued at $9,814,000 after purchasing an additional 2,887 shares during the period. AE Wealth Management LLC grew its position in Pfizer by 19.7% in the 4th quarter. AE Wealth Management LLC now owns 249,525 shares of the biopharmaceutical company’s stock valued at $9,776,000 after purchasing an additional 41,038 shares during the period. Investors Asset Management of Georgia Inc. GA ADV grew its position in Pfizer by 0.5% in the 4th quarter. Investors Asset Management of Georgia Inc. GA ADV now owns 54,129 shares of the biopharmaceutical company’s stock valued at $2,121,000 after purchasing an additional 250 shares during the period. Farmers Trust Co. grew its position in Pfizer by 0.4% in the 4th quarter. Farmers Trust Co. now owns 177,566 shares of the biopharmaceutical company’s stock valued at $6,957,000 after purchasing an additional 690 shares during the period. Finally, Wedge Capital Management L L P NC grew its position in Pfizer by 8,853.8% in the 4th quarter. Wedge Capital Management L L P NC now owns 1,061,826 shares of the biopharmaceutical company’s stock valued at $41,602,000 after purchasing an additional 1,049,967 shares during the period. 70.21% of the stock is owned by institutional investors.

Several analysts recently issued reports on PFE shares. Credit Suisse Group reissued a “hold” rating and issued a $41.30 price target on shares of Pfizer in a research report on Wednesday, November 6th. ValuEngine raised shares of Pfizer from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Pfizer in a research report on Tuesday, October 29th. Zacks Investment Research raised shares of Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 price objective on the stock in a report on Tuesday, October 1st. Finally, Bank of America assumed coverage on shares of Pfizer in a report on Wednesday, October 16th. They set a “neutral” rating and a $37.00 price objective on the stock. Nine analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $43.41.

NYSE PFE opened at $40.67 on Thursday. The stock has a market capitalization of $221.75 billion, a price-to-earnings ratio of 13.56, a PEG ratio of 4.24 and a beta of 0.65. Pfizer Inc. has a one year low of $33.97 and a one year high of $44.56. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.90 and a quick ratio of 0.68. The business’s fifty day moving average is $38.90 and its 200-day moving average is $38.18.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the Zacks’ consensus estimate of $0.62 by $0.13. The company had revenue of $12.68 billion for the quarter, compared to analysts’ expectations of $12.37 billion. Pfizer had a return on equity of 28.10% and a net margin of 30.57%. The business’s revenue for the quarter was down 4.6% compared to the same quarter last year. During the same period in the previous year, the business posted $0.78 EPS. Research analysts expect that Pfizer Inc. will post 2.97 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 31st will be paid a dividend of $0.38 per share. This represents a $1.52 dividend on an annualized basis and a dividend yield of 3.74%. This is a boost from Pfizer’s previous quarterly dividend of $0.36. The ex-dividend date of this dividend is Thursday, January 30th. Pfizer’s payout ratio is presently 48.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Read More: What is a portfolio manager?

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.